Impact of in Vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: Enhanced efficacy against Cyp51 mutant isolates

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5438-5447

  Lepak, Alexander J ^a   Marchillo, Karen ^a   VanHecker, Jamie ^a   Andes, David R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; POSACONAZOLE; STEROL 14ALPHA DEMETHYLASE;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; COMBINATION CHEMOTHERAPY; CONIDIUM; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; FEMALE; FUNGAL PHENOMENA AND FUNCTIONS; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; FUNGUS MUTANT; IN VIVO STUDY; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; MURINE MODEL; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ASPERGILLUS FUMIGATUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MICE; MICROBIAL SENSITIVITY TESTS; SPORES, FUNGAL; TRIAZOLES;

EID: 84885919936     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00833-13     Document Type: Article

References (58)

1. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG. 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin. Infect. Dis. 50:1091-1100.
2. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50:1101-1111.
3. Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, Oster RA, Anaissie EJ, Walsh TJ, Schuster MG, Wingard JR, Patterson TF, Ito JI, Williams OD, Chiller T, Pappas PG. 2010. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin. Infect. Dis. 50:1559-1567.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. 22 November 2012, accession date. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC. http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf.
5. Centers for Disease Control and Prevention. 2003. Treatment of tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Recomm. Rep. 52(RR-11):1-77.
6. Abad CL, Kumar A, Safdar N. 2011. Antimicrobial therapy of sepsis and septic shock -when are two drugs better than one? Crit. Care Clin. 27:e1-27.
7. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111: e394-e434.
8. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322.
9. Johnson MD, Perfect Jr. 2010. Use of antifungal combination therapy: agents, order, and timing. Curr. Fungal Infect. Rep. 4:87-95.
10. Segal BH, Steinbach WJ. 2007. Combination antifungals: an update. Expert Rev. Anti Infect. Ther. 5:883-892.
11. Steinbach WJ, Stevens DA, Denning DW. 2003. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin. Infect. Dis 37(Suppl 3):S188-S224.
12. Vazquez JA. 2008. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing? Clin. Infect. Dis. 46:1889-1901.
13. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.
14. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
15. Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE. 2005. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin. Infect. Dis. 41:1448-1452.
16. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect Jr. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12.
17. Chandrasekar PH. 2005. Antifungal resistance in aspergillus. Med. Mycol. 43(Suppl 1):S295-S298.
18. Denning DW, Perlin DS. 2011. Azole resistance in Aspergillus: a growing public health menace. Future Microbiol. 6:1229-1232.
19. Howard SJ, Arendrup MC. 2011. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med. Mycol. 49(Suppl 1):S90 -S95.
20. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
21. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219. doi:10.1371/journal.pmed.0050219.
22. Clinical and Laboratory Standards Institute. 2008. Refence method for broth dilution antifungal susceptbility testing of filamentous fungi. Approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
23. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
24. Lepak A, Sanchez H, Marchillo K, Andes D. 2010. Comparative pharmacodynamics of a triazole and echinocandin for invasive pulmonary aspergillosis. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. http://www.icaac.org/.
25. Andes D, Craig WA. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
26. Lewis RE, Liao G, Hou J, Prince RA, Kontoyiannis DP. 2011. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus. J. Antimicrob. Chemother. 66:1324-1331.
27. Lewis RE, Albert ND, Kontoyiannis DP. 2008. Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 52:4178-4180.
28. Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. 2006. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50:469-473.
29. Bowman JC, Abruzzo GK, Anderson JW, Flattery AM, Gill CJ, Pikounis VB, Schmatz DM, Liberator PA, Douglas CM. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:3474-3481.
30. Vallor AC, Kirkpatrick WR, Najvar LK, Bocanegra R, Kinney MC, Fothergill AW, Herrera ML, Wickes BL, Graybill JR, Patterson TF. 2008. Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. Antimicrob. Agents Chemother. 52:2593-2598.
31. Walsh TJ, McEntee C, Dixon DM. 1987. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J. Clin. Microbiol. 25:931-932.
32. Herrera ML, Vallor AC, Gelfond JA, Patterson TF, Wickes BL. 2009. Strain-dependent variation in 18S ribosomal DNA copy numbers in Aspergillus fumigatus. J. Clin. Microbiol. 47:1325-1332.
33. Andes D, Marchillo K, Conklin R, Krishna G, Ezzet F, Cacciapuoti A, Loebenberg D. 2004. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 48:137-142.
34. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob. Agents Chemother. 54: 2497-2506.
35. Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW. 2011. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J. Infect. Dis. 203:1324-1332.
36. Mavridou E, Bruggemann RJ, Melchers WJ, Mouton JW, Verweij PE. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865.
37. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. 2005. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob. Agents Chemother. 49:5058-5068.
38. Bliss CI. 1939. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26:585-615.
39. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF. 2006. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J. Infect. 53:337-349.
40. Kontoyiannis DP, Ratanatharathorn V, Young JA, Raymond J, Laverdiere M, Denning DW, Patterson TF, Facklam D, Kovanda L, Arnold L, Lau W, Buell D, Marr KA. 2009. Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. Transplant Infect. Dis. 11:89 -93.
41. Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, Killar J, Taylor A, Kartsonis N, Patterson TF, Aoun M, Caillot D, Sable C. 2006. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107:2888-2897.
42. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. 2004. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 39:797-802.
43. Singh N, Limaye AP, Forrest G, Safdar N, Munoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del Busto R, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, Husain S. 2006. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81:320-326.
44. Thomas A, Korb V, Guillemain R, Caruba T, Boussaud V, Billaud E, Prognon P, Begue D, Sabatier B. 2010. Clinical outcomes of lungtransplant recipients treated by voriconazole and caspofungin combination in aspergillosis. J. Clin. Pharm. Ther. 35:49-53.
45. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. 2010. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 54:4758-4764.
46. Lepak AJ, Marchillo K, Vanhecker J, Andes DR. 2013. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 57:579-585.
47. Petraitiene R, Petraitis V, Groll AH, Sein T, Schaufele RL, Francesconi A, Bacher J, Avila NA, Walsh TJ. 2002. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. 46:12-23.
48. Ingham CJ, Schneeberger PM. 2012. Microcolony imaging of Aspergillus fumigatus treated with echinocandins reveals both fungistatic and fungicidal activities. PLoS One 7:e35478. doi:10.1371/journal.pone.0035478.
49. Lamaris GA, Lewis RE, Chamilos G, May GS, Safdar A, Walsh TJ, Raad II, Kontoyiannis DP. 2008. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J. Infect. Dis. 198:186-192.
50. Greco WR, Bravo G, Parsons JC. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
51. Marr KA, Schlamm H, Rottinghaus ST, Jagannatha S, Bow EJ, Wingard JR, Pappas P, Herbrecht R, Walsh TJ, Maertens J. 2012. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis, abstr LB 2812. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis.
52. Chandrasekar PH, Cutright JL, Manavathu EK. 2004. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin. Microbiol. Infect. 10:925-928.
53. Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. 2002. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. 46:2564-2568.
54. MacCallum DM, Whyte JA, Odds FC. 2005. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob. Agents Chemother. 49:3697-3701.
55. Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, Cotton MP, Stergiopoulou T, Kasai M, Francesconi A, Schaufele RL, Sein T, Avila NA, Bacher J, Walsh TJ. 2009. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration-and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob. Agents Chemother. 53:2382-2391.
56. van de Sande WW, Mathot RA, ten Kate MT, van Vianen W, Tavakol M, Rijnders BJ, Bakker-Woudenberg IA. 2009. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob. Agents Chemother. 53:2005-2013.
57. Seyedmousavi S, Bruggemann RJ, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW. 2012. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J. Antimicrob. Chemother.
58. Jeans AR, Howard SJ, Al-Nakeeb Z, Goodwin J, Gregson L, Warn PA, Hope WW. 2012. Combination of voriconazole and anidulafungin for treatment of triazole-resistant Aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 56: 5180-5185.